News

Dec 19, 2022

Mabwell Was Ranked in the "List of New and Innovative Chinese Pharmaceutical Forces"

➞

Dec 01, 2022

Mabwell Published Pre-clinical Study Results of CD47/PD-L1 Bi-specific Antibody 6MW3211

➞

Nov 23, 2022

Dr. Liu Datao, Co-founder and CEO of Mabwell, was Honored as “Sci-Tech Innovation Board Leaders，2022”

➞

Nov 22, 2022

Mabwell and Junshi Announce the Approval of Five Indications for Adalimumab

➞

Nov 21, 2022

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

➞

Nov 18, 2022

Dr. Liu Datao, CEO of Mabwell, Was Invited to Participate in the Live Interview of "International Biopharma Industry Week Shanghai 2022" by Yicai

➞

Nov 16, 2022

Mabwell Awarded "Zhangjiang Life Science Industry New Prominent · 2022"

➞

Nov 11, 2022

Mabwell Ranked the List of Top 20 Most Influential Antibody Pharmaceutical Companies in China 2022

➞

Oct 21, 2022

Wu Zhiyuan, Director of Development Research Center of People's Government of Pudong New Area, and His Entourage Visited Mabwell for Research and Guidance

➞

Oct 19, 2022

First in Class! Mabwell's Clinical Trial Application for 9MW3011 Injection - An Innovative Drug Accepted by NMPA

➞